We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Malaria Severity Not Determined Solely by Parasitemia

By LabMedica International staff writers
Posted on 26 May 2014
The relative contributions of such factors as the concentration level of malaria-causing parasites in a person's blood to disease severity and to development of protective immunity are not adequately understood. More...


In areas where transmission is stable, severe malaria is unlikely to occur after five years of age, presumably as a result of immunity, and mathematical models suggest that protection against noncerebral severe malaria develops after one or two infections.

A team of international scientists led by those at the US National Institutes of Health (Rockville, MD, USA) enrolled 882 newborns in the study as part of a longitudinal birth cohort between September 2002 and November 2005, in Muheza (Tanzania). Children were followed for an average of two years and for as long as four years. Children were examined at birth, once every two weeks during infancy, once every month after infancy, and during any illness. Blood smears were collected at all visits, regardless of whether symptoms were present.

Parasitemia was defined as any Plasmodium falciparum detected in a Giemsa-stained blood smear, and high-density infection requiring parenteral treatment was defined as a parasite density of more than 2,500 parasites per 200 white cells. P. falciparum-specific histidine-rich protein 2 plasma concentrations were determined during infection in all available samples from the cohort, which included 475 samples from the children who suffered severe malaria. Samples were tested using an in-house double-site sandwich enzyme-linked immunosorbent assay (ELISA). Hemoglobin type (HbAA, HbAS, and HbSS) was determined by cellulose acetate paper electrophoresis (Helena Laboratories; Beaumont, Texas, USA).

The scientist found that no simple relationship between parasite density and malaria severity emerged. Of the 102 children who did develop severe malaria at least once while enrolled in the study, almost two-thirds had high parasite density, but only mild disease either before or after the episode of severe malaria. This data suggest that one or two mild episodes of malaria are not sufficient to eliminate the risk of severe malaria which is contrary to predictions made by some mathematical models. The team noted that this prospective study is the first to provide direct evidence that severe malaria risk is stable over several infections.

The authors concluded they have provided direct evidence that severe malaria is unlikely to recur but that it commonly occurs after previous infections, including high-density infections. The immunity to severe malaria is not related to improved control of parasite density. The epidemiologic evidence suggests that naturally acquired immunity targets a conserved feature of the various severe-malaria syndromes, such as parasite virulence or host inflammation. The study was published on May 8, 2014, in the New England Journal of Medicine (NEJM).

Related Links:
National Institutes of Health 
Helena Laboratories 



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.